KVD824 Prototype 1 modified-release tablet
KVD824-102
Phase 1 small_molecule completed
Quick answer
KVD824 Prototype 1 modified-release tablet for Hereditary Angioedema is a Phase 1 program (small_molecule) at Kalvista Pharmaceuticals (Ireland) Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Kalvista Pharmaceuticals (Ireland) Limited
- Indication
- Hereditary Angioedema
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed